Here, we report a 47‐year‐old man with pleomorphic cMCL carrying a TP53 mutation that, due to chemotherapy resistance and high tumour burden disease, was initially treated with ibrutinib + venotoclax as bridging to CAR T cell therapy. The gene discussed is TP53; the disease is neoplasm.